Antihypertensive efficacy of the ACE-inhibitor perindopril in the elderly

Journal of Human Hypertension

Volumn 14, Issue 5, 2000, Pages 321-325

  Leenen, Frans H H ^a   Tanner, J ^b   McNally, C F ^c  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b General Practice Research Group   (Canada)

^c Clinical Research Partners   (United States)

Author keywords

ACE inhibitor; Elderly; Hypertension; Placebo

Indexed keywords

PERINDOPRIL;

AGED; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE;

EID: 0034026642     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001004     Document Type: Article

References (17)

1. Thijs L et al. A meta-analysis of outcome trials in elderly hypertensives. J Hypertens 1992; 10: 1103-1109.
2. Staessen JA et al. Randomized double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
3. Bühler FR. Age and cardiovascular response adaptation: determinants of an antihypertensive treatment concept primarily based on beta-blockers and calcium entry blockers. Hypertension 1983; 5 (Suppl III): III-94-III-100.
4. Bielen E, Fagard R, Lijnen P, Amery A. The effect of aging on the plasma renin-angiotensin-aldosterone system in elderly hypertensive patients. J Hum Hypertens 1988; 2: 167-170.
5. Israili ZH, Hall WD. ACE inhibitors. Differential use in elderly patients with hypertension. Drugs & Aging 1995; 7: 355-371.
6. Atkinson J. Perindopril. Cardiovasc Drug Rev 1992; 10: 446-471.
7. Speirs C, Wagniart F, Poggi L. Perindopril postmarketing surveillance: a 12 month study in 47,351 hypertensive patients. Br J Clin Pharmacol 1998; 46: 63-70.
8. Tan KW, Leenen FHH. Persistence of anti-hypertensive effect after missed dose of perindopril. Can J Cardiol 1998; 14 (Suppl F): 149F (Abstract).
9. Chrysant SG et al. Perindopril as monotherapy in hypertension: a multicenter comparison of two dosing regimens. Clin Pharmacol Ther 1993; 53: 479-484.
10. Suraniti S, Berrut G, Marre M, Fressinaud P. The antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients. Am J Cardiol 1993; 71: 28E-31E.
11. Tcherdakoff P. Long-term evaluation of the antihypertensive activity of coversyl (perindopril) in 26,008 treated, uncontrolled hypertensive patients. JAMA 1995; 307: 1-10.
12. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413-2446.
13. Myers MG. A dose-response study of perindopril in hypertension: effects of blood pressure 6 and 24 h after dosing. Can J Cardiol 1996; 12: 1191-1196.
14. Kassler-Taub K et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998; 11: 445-453.
15. Materson BJ, Preston RA, Reda DJ, Williams D. Placebo-associated blood pressure response and adverse effects. Am J Hypertens 1999; 12: 43A (Abstract).
16. Marceau M, Kouame N, Lacourciere Y, Cleroux J. Vascular structure in the forearm and calf after 6 months of angiotensin converting enzyme inhibition in elderly hypertensive subjects with left ventricular hypertrophy. J Hypertens 1998; 16: 673-679.
17. Chrysant SG et al. Antihypertonsive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. Arch Intern Med 1994; 154: 737-743.